Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.35 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20409958 | 0.89 | CNR2 (0.38) | CNR2 | |
| SCHEMBL20409651 | 0.86 | ENPP3 (0.36) | ENPP1ENPP3MAPK1PTPN11CA12 | |
| SCHEMBL20409619 | 0.85 | CNR2 (0.35) | MAPK1CNR2CYP11B1CYP11B2NPC1 | |
| SCHEMBL20409672 | 0.82 | KDM4E (0.35) | ENPP1ENPP3MAPK1PTPN11NPC1 | |
| SCHEMBL20409647 | 0.81 | CHRNA1 (0.38) | ENPP1ENPP3MAPK1CA12CA9 | |
| SCHEMBL20409665 | 0.81 | ENPP1 (0.36) | ENPP1ENPP3MAPK1PTPN11CA12 | |
| SCHEMBL20409970 | 0.81 | CNR2 (0.36) | CNR2 | |
| SCHEMBL20409662 | 0.80 | KDM4E (0.48) | ENPP1ENPP3MAPK1PTPN11MAPK3 | |
| SCHEMBL20409722 | 0.80 | CNR2 (0.33) | MAPK1CNR2CYP11B1CYP11B2MAPT | |
| SCHEMBL20409911 | 0.78 | CNR2 (0.34) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11342511-B2 | Azoline ring-containing compound, electron transport/injection layer material containing the same, and organic electroluminescent element using the same | SK MATERIALS JNC CO., LTD. (KR) | 2022-05-24 | — | — | US | disclosed |
| US-20180212156-A1 | AZOLINE RING-CONTAINING COMPOUND, ELECTRON TRANSPORT/INJECTION LAYER MATERIAL CONTAINING THE SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | JNC CORPORATION (JP) | 2018-07-26 | — | — | US | disclosed |
| US-20180212156-A1 | AZOLINE RING-CONTAINING COMPOUND, ELECTRON TRANSPORT/INJECTION LAYER MATERIAL CONTAINING THE SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | JNC CORPORATION (JP) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11342511-B2 | Azoline ring-containing compound, electron transport/injection layer material containing the same, and organic electroluminescent element using the same | SLC7A5, EML4, ARNT | ENPP1 3858/4885ENPP3 3900/4885MAPK1 901/4885 |
| US-20180212156-A1 | AZOLINE RING-CONTAINING COMPOUND, ELECTRON TRANSPORT/INJECTION LAYER MATERIAL CONTAINING THE SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | SLC7A5, EML4, ARNT | ENPP1 3858/4885ENPP3 3900/4885MAPK1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.